Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[The new heparins].

M Samama

    Presse Medicale (Paris, France : 1983)
    |September 27, 1986
    PubMed
    Summary
    This summary is machine-generated.

    New low molecular weight heparins offer improved antithrombotic activity and bioavailability compared to standard heparin. These heparins demonstrate reduced pro-platelet aggregation, enhancing their safety profile for surgical patients.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Intra-sinusal bone ring concomitant with Le Fort 1 osteotomy: description of a technique.

    Journal of stomatology, oral and maxillofacial surgery·2020
    Same author

    Mandibular lymphoma.

    Journal of stomatology, oral and maxillofacial surgery·2017
    Same author

    Prevention and treatment of venous thromboembolism--International Consensus Statement.

    International angiology : a journal of the International Union of Angiology·2014
    Same author

    [Two new anticoagulants available in 2010--Dabigatran Etexilate and Rivaroxaban: expected progresses--raised problems].

    Annales pharmaceutiques francaises·2010
    Same author

    Recommendations on biosimilar low-molecular-weight heparins.

    Journal of thrombosis and haemostasis : JTH·2009
    Same author

    An international multicenter randomized study of computer-assisted oral anticoagulant dosage vs. medical staff dosage.

    Journal of thrombosis and haemostasis : JTH·2008
    Same journal

    Predictive analytics and risk stratification models in internal medicine: from risk scores to real-time machine learning.

    Presse medicale (Paris, France : 1983)·2026
    Same journal

    Artificial Intelligence in skin disease therapeutics: from drug discovery to personalized treatment pathways.

    Presse medicale (Paris, France : 1983)·2026
    Same journal

    AI in clinical diagnostics in dermatology: applications, validation, and real-world use cases.

    Presse medicale (Paris, France : 1983)·2026
    Same journal

    Artificial Intelligence in medical research and publishing: progress, risks, and future perspectives.

    Presse medicale (Paris, France : 1983)·2026
    Same journal

    Ethical, legal, and regulatory challenges in AI-based healthcare tools.

    Presse medicale (Paris, France : 1983)·2026
    Same journal

    Beyond one-size-fits-all: Personalising health communication to drive real behaviour change.

    Presse medicale (Paris, France : 1983)·2026
    See all related articles

    Area of Science:

    • Pharmacology
    • Biochemistry

    Context:

    • Standard heparin preparations are heterogeneous with varying molecular weights.
    • Low molecular weight heparins (LMWH) are less heterogeneous, with a mean molecular weight of approximately 5,000 daltons.

    Purpose:

    • To compare the pharmacological and clinical properties of LMWH with standard heparin.
    • To evaluate the efficacy and safety of LMWH in preventing venous thromboembolism.

    Summary:

    • LMWH exhibits similar anti-factor Xa activity to standard heparin but has a longer half-life and significantly higher subcutaneous bioavailability (>90% vs. <30%).
    • While LMWH has lower anticoagulant activity (activated cephalin time), its antithrombotic efficacy in preventing deep vein thrombosis in general surgery is comparable to standard heparin with less frequent dosing.
    • LMWH preparations are largely devoid of the pro-platelet aggregation effects associated with standard heparin.

    Related Experiment Videos

    Impact:

    • LMWH offers a more predictable pharmacokinetic profile and improved safety, particularly regarding bleeding risk.
    • The enhanced bioavailability and efficacy of LMWH support its use as a preferred anticoagulant in surgical prophylaxis.
    • LMWH represents a significant advancement in anticoagulant therapy, offering better patient outcomes and potentially reduced healthcare costs.